Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Thromb Res. 2013 Nov 6;133(2):203–210. doi: 10.1016/j.thromres.2013.10.043

Fig. 4. Effect of combined ex vivo addition of 2MeSAMP and MRS 2179 on platelet function in comparison to ex vivo addition of 2MeSAMP or MRS 2179 alone.

Fig. 4

(A) Platelet fluorescence dynamics over time in the presence of ex vivo 2MeSAMP, MRS 2179, or combined 2MeSAMP and MRS 2179. (B) Ex vivo addition of 2MeSAMP and MRS 2179 reduced final thrombus size more significantly than 2MeSAMP or MRS 2179 treatment alone when normalized against final control thrombus size over collagen (p < 0.01, n = 8 donors). (C) RP2Y for combined ex vivo 2MeSAMP and MRS 2179 addition. Error bars indicate standard deviation from 6 measurements of RP2Y for each donor.